Explore the Gallagher resource library

At Arthur J. Gallagher & Co., we try to learn everything we can about the industries we serve and the risks they may encounter. It’s a commitment that’s embedded in our corporate culture to expanding our expertise, continuing educational development and gathering topical updates to remain ahead of the curve.

1 - 10 of 13 items [Currently showing All Items in Life Sciences]

Q3 Market Update 2018

The market is always fluctuating, and though some anticipated a significant market tightening in 2018 as a result of the catastrophic events that occurred at the end of 2017, the threat of a near term correction has largely dissipated.

Tag(s): Market Update;

A New Cyber Alarm for Life Sciences Companies?

Life sciences companies, previously considered low-value cyberattack targets because they often don’t have much easily monetized PII or PHI, avoided much of the early negative cyber publicity. That may change with the SEC’s February 2018 interpretive guidance to public companies’ cybersecurity disclosure obligations.

Tag(s): Life Sciences; Cyber Liability;

Medical Device Cybersecurity

The world of cyber risk continues to develop and expand since our May 2016 paper on Medical Device Cybersecurity. The threat of ransomware has come to the forefront as demonstrated by global attacks such as Wannacry2 and Petya. These attacks show how hackers have become more sophisticated in their ability to use malware to exploit vulnerabilities in systems, hardware and devices, as well as highlighting the vulnerabilities of devices and systems that, through their lack of patching and support, and outdated operating systems, are exposed to hacking, worms, etc., that can affect patient safety, system security and data integrity.

Tag(s): Healthcare; Cyber Risk; Cyber Liability; Life Sciences; Management Liability;

The Double Helix: Winter 2017

Welcome to the winter edition of The Double Helix. Inside this issue you can find articles on the following: Medical Device Consolidation, FDA Regulations, 3D Printing and the Life Sciences Market and Clinical Trials Overseas.

Tag(s): Life Sciences;

Synthetic Biology: The Future is Now

Biotechnology and specifically Synthetic Biology (SynBio) is evolving at lightning speed. SynBio makes it possible to engineer life from the ground up (allowing the formation of organisms with genetic code (DNA) not found in the natural world) and to re-design existing natural bio systems for life-changing purposes. The opportunities are limitless and so are the risks.

Tag(s): Life Sciences; Synthetic Biology; Biotechnology;